Cargando…
Patterns of resource utilization and cost for postmenopausal women with hormone-receptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer in Europe
BACKGROUND: Healthcare resource utilization in breast cancer varies by disease characteristics and treatment choices. However, lack of clarity in guidelines can result in varied interpretation and heterogeneous treatment management and costs. In Europe, the extent of this variability is unclear. The...
Autores principales: | Jerusalem, Guy, Neven, Patrick, Marinsek, Nina, Zhang, Jie, Degun, Ravi, Benelli, Giancarlo, Saletan, Stephen, Ricci, Jean-François, Andre, Fabrice |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619560/ https://www.ncbi.nlm.nih.gov/pubmed/26498283 http://dx.doi.org/10.1186/s12885-015-1762-3 |
Ejemplares similares
-
Patients’ preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan
por: Omori, Yukie, et al.
Publicado: (2019) -
Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers
por: Migliaccio, Ilenia, et al.
Publicado: (2015) -
Real-World Treatment Patterns for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Europe and the United States
por: Caldeira, Rita, et al.
Publicado: (2016) -
Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
por: Abdel-Razeq, Hikmat
Publicado: (2016) -
Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
por: Gradishar, William J
Publicado: (2016)